$ALNY received 12 mentions from 3 distinct FinTwit voices over the 12-month period from September 2025 to July 2026, with @adamfeuerstein accounting for all 12 mentions, making him the dominant voice discussing Alnylam Pharmaceuticals. The biotech sector represented the primary discussion category for this ticker. The first mention appeared on September 11, 2025, while the most recent activity occurred on July 9, 2026.

Recent discourse centered on competitive dynamics within the ATTR-CM (transthyretin cardiac amyloidosis) treatment landscape. On July 9, 2026, @adamfeuerstein noted that following the failure of a competing heart disease drug, Alnylam's Amvuttra "stands alone" while questioning the status of nucresiran, another treatment option. Earlier that day, the same voice reported that $ALNY shares rose 16 percent following news that AstraZeneca and Ionis reported a major trial failure with their competing therapy. In June, @adamfeuerstein referenced $ALNY alongside other underperforming biotech companies in the broader market context.